Regulations on excipients used in 3D printing of pediatric oral forms

• Published in: International journal of pharmaceutics 2024-09, Vol.662, p.124402, Article 124402
• Main Authors: Monteil, M., M.Sanchez-Ballester, N., Devoisselle, J.M., Begu, S., Soulairol, I.
• Format: Article
• Language: English
• Subjects: 3D printing; Chemical Sciences; Excipients; Pediatric; Safety; Toxicity
• ISSN: 0378-5173; 1873-3476; 1873-3476
• DOI: 10.1016/j.ijpharm.2024.124402

[Display omitted] A promising solution to customize oral drug formulations for the pediatric population has been found in the use of 3D printing, in particular Fused Deposition Modeling (FDM) and Semi-Solid Extrusion (SSE). Although formulation development is currently limited to research studies, the rapid advances in 3D printing warn of the need for regulation. Indeed, even if the developed formulations include pharmaceutical excipients used to produce traditional oral forms such as tablets, the quantities of excipients used must be adapted to the process. Therefore, the aim of this literature review is to provide a synthesis of the available safety data on excipients mainly used in extrusion-based 3D printing for the pediatric population. A total of 39 relevant articles were identified through two scientific databases (PubMed and Science Direct). Then, groups of the main excipients were listed including their general information (name, chemical structure and pharmaceutical use) and a synthesis of the available safety data extracted from several databases. Finally, the role of the excipients in 3D printing, the amount used in formulations and the oral dose administered per form are presented.